<DOC>
	<DOCNO>NCT02258451</DOCNO>
	<brief_summary>The objective study assess efficacy safety radium 223 dichloride subject human epidermal growth factor receptor 2 ( HER2 ) negative hormone receptor positive breast cancer bone metastasis treat exemestane everolimus .</brief_summary>
	<brief_title>Study Radium-223 Dichloride Versus Placebo Treatment With Exemestane / Everolimus Subjects With Bone Predominant HER2 ( Human Epidermal Growth Factor Receptor 2 ) Negative Hormone Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Women ( â‰¥18 year age ) metastatic breast cancer amenable curative treatment surgery radiotherapy . Documentation histological cytological confirmation estrogen receptor positive ( ER+ ) HER2 negative adenocarcinoma breast must available . Documentation menopausal status : postmenopausal subject premenopausal subject ovarian radiation concomitant therapy luteinizing hormonereleasing hormone ( LHRH ) agonist/antagonist eligible . Subjects bone dominant disease least 2 skeletal metastasis identify baseline bone scintigraphy confirm compute tomography ( CT ) /magnetic resonance imaging ( MRI ) . Subjects must receive least one line hormonal therapy metastatic setting . Subjects eligible per Investigator 's assessment accord local label treatment exemestane everolimus second line great hormone therapy metastatic setting . Subjects must experience recurrent/progressive disease follow treatment nonsteroidal aromatase inhibitor ( letrozole anastrozole ) adjuvant metastatic setting Subjects must experience two skeletalrelated event ( SREs ) prior study entry define : need external beam radiotherapy ( EBRT ) bone pain , pathological bone fracture ( exclude major trauma ) , spinal cord compression and/or orthopedic surgical procedure . Subjects prior SREs permit . Subjects must therapy bisphosphonates denosumab least 1 month start study treatment . Adequate hematological , liver kidney function . Subjects Inflammatory breast cancer . Patients immediately lifethreatening visceral disease chemotherapy prefer treatment option . Subjects either received chemotherapy metastatic disease consider treat investigator appropriate candidate chemotherapy current treatment metastatic breast cancer exclude . Chemotherapy administer adjuvant/neo adjuvant disease acceptable provide administer least 1 year prior study entry . Subjects received prior treatment already receive everolimus treatment prior study entry eligible . Subjects know history brain metastasis leptomeningeal disease : subject neurological symptom must undergo contrast CT scan MRI brain within 28 day prior randomization exclude active brain metastasis . Imaging central nervous system ( CNS ) otherwise require .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>